Outsourcing in Clinical Trials Nordics 201417-18 September 2014, Copenhagen, Denmark
With healthcare innovation and growth being considered a top priority for the Nordic region, clinical trials are regarded as a key aspect of delivery innovation, with governments incentivising and rewarding such efforts. One of the key considerations for the Nordics is the need for collaboration. Furthermore, with the increased rewards for innovation, the industry is looking to increase R&D activity, which in turn means there will be considerable development within clinical trials. Against this backdrop, OCT Nordics will allow companies from within this Nordic-specific hub to come together and discuss proven strategies to improve and create partnerships within clinical trials and medical devices.
Alongside the biopharmaceutical outsourcing sessions, we will also include unique medical device-specific sessions in a separate stream covering: medical device outsourcing, patient recruitment and new regulations (e.g. MDD). This year’s event will have more of an operational focus and bring together senior industry representatives to discuss the latest challenges within clinical outsourcing and medical device-related challenges such as: improved vendor communication strategies, vendor sourcing/selection, budgeting and contracting, oversight and management, patient recruitment, risk-based monitoring and feasibility plans.
Outsourcing in Clinical Trials Nordics 2014 promises to be a highly engaging meeting and will present a unique platform for discussion alongside thought-sharing on innovative strategies within outsourcing models in this ever-growing region.
On behalf of World Courier and Arena International, we wish to cordially invite all attendees at the upcoming Outsourcing in Clinical Trials Nordic Conference to a first evening drinks reception to be held immediately following the conclusion of Day 1 activities.
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Primary delegates for this event are those with responsibility for clinical outsourcing in biotech and pharma companies within the Nordic region.
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Testimonials from other events in our Outsourcing in Clinical Trials Series
AbbVie, the development partner of Enanta Pharmaceuticals for protease inhibitors for hepatitis C virus (HCV), has started a Phase IIb clinical trial with Enanta’s next-generation protease inhibitor ABT-493.
US-based biopharmaceutical firm PTC Therapeutics has completed patient enrolment in ACT DMD, the Phase III confirmatory trial of Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy (nmDMD).
US-based pharmaceutical firm Lipocine has dosed the first patient in a Phase I trial of LPCN 1107, an oral hydroxyprogesterone caproate (HPC) product candidate, for preventing preterm birth in pregnant women.
US-based biopharmaceutical firm CytRx has started patient enrolment in an open-label Phase Ib clinical trial of aldoxorubicin plus ifosfamide/mesna as a first-line treatment in subjects with various sarcomas.
Mundipharma has reported results from a randomised, multicentre, Phase III trial of flutiform, a combination of fluticasone propionate and formoterol in a single pressurised metered dose inhaler, to treat paediatric asthma.
Boehringer Ingelheim Pharmaceuticals has reported data from the pivotal Phase III TONADO I and II trials (NCT01431274/NCT01431287) for the fixed-dose combination (FDC) of tiotropium, plus olodaterol to treat patients with moderate to very severe chr…